[Introduction of platelet additive solutions in transfusion practice. Advantages, disadvantages and benefit for patients].
Platelet additive solutions (PAS) have been developed since the years 1980. However, decisive improvements have been made in the last five years, leading nowadays to several PAS available for transfusion practice. Few compounds are present in PAS, with the intention of controlling platelet metabolic alterations and activation that occur during storage: acetate, which is a substrate for the tricarboxylic acid cycle, enables to maintain oxidative metabolism, is present in all PAS; a buffer effect is required to prevent the progressive pH fall during storage, and is obtained either with sodium phosphate or gluconate; platelet activation is controlled by citrate, and in the latest PAS, by magnesium and potassium. It is important to note that whatever the PAS used, it is mandatory to maintain a final concentration of 20-40% of plasma, mainly in order to ensure glucose availability. The use of PAS leads to a more rationalized blood processing, as it provides an additional volume of plasma available for plasma fractionation, it contributes to standardization of blood components, and it is part of at least one pathogen reduction process. The expected benefit for patient is the reduction of adverse reactions related to plasma. There is already evidence that the incidence of allergic adverse reactions is reduced. In the case of other less frequent adverse reactions such as transfusion related acute lung injury (TRALI) or haemolytic reaction due to minor ABO incompatibility, only a long-term follow-up through haemovigilance organization will be informative.
Andreu
Georges
G
Institut national de la transfusion sanguine, 6 rue Alexandre-Cabanel, 75739 Paris cedex 15, France. gandreu@ints.fr
Vasse
Julie
J
Hervé
Françoise
F
Tardivel
René
R
Semana
Gilbert
G
D000085:Acetates / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D001793:Blood Preservation / Q000379:methods; D002951:Citrates / Q000097:blood; D006801:Humans; D008274:Magnesium / Q000097:blood; D010710:Phosphates / Q000097:blood; D017713:Platelet Transfusion / Q000009:adverse effects / Q000379:methods*; D011188:Potassium / Q000097:blood; D011310:Preservatives, Pharmaceutical; D012996:Solutions; D016896:Treatment Outcome
D000085:Acetates; D001786:Blood Glucose; D002951:Citrates; D010710:Phosphates; D011310:Preservatives, Pharmaceutical; D012996:Solutions; D008274:Magnesium; D011188:Potassium